LR Health & Beauty SE reported on its business development in the third quarter of 2025. Sales during the period reached $76.8 million, with the first nine months cumulatively driving $242.9 million in sales. This cumulative amount represents a 1.8% decrease year-over-year. EBITDA during the quarter was $3.37 million, representing a “significant decline” of 59.9% year-over-year. As a result, EBITDA for the first nine months of 2025 was $18.9 million.
The company experienced positive momentum with the successful relaunch of its fragrance segment in September and believes its current inventory will create a “well-stocked product pipeline” to create additional business opportunities for distributors.
“In a market environment still characterized by high uncertainty and restrained consumer spending, we focus on deliberately strengthening the operating performance of the LR Group,” said Jörg Körfer, LR Health & Beauty SE CEO. “The continuous optimization and expansion of our product portfolio – most recently through the successful market launch of innovative fragrance lines – is an important strategic pillar. In addition, we want to align our processes even more closely with the needs of our distributors. The successfully conducted Business Days in September once again made it clear that together with our strong partner community, we can accomplish a great deal and make even better use of the potential in our business areas.”
The company now expects full-year 2025 sales to be in the range of $321 million to $327 million.
“Our mission is clear: We want to make the LR Group operationally and financially sustainable for the future,” Körfer said. “From a financial point of view, we are in talks with the bond creditors of the 2024/2028 bond and have commissioned a restructuring report for support. This is intended to assist to develop an appropriate action plan for the company and to improve the capital and financing structure of the LR Group sustainably with appropriate measures.”
